0001209191-21-043811.txt : 20210629 0001209191-21-043811.hdr.sgml : 20210629 20210629195558 ACCESSION NUMBER: 0001209191-21-043811 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210625 FILED AS OF DATE: 20210629 DATE AS OF CHANGE: 20210629 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McClung David Mark CENTRAL INDEX KEY: 0001811505 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30171 FILM NUMBER: 211059827 MAIL ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC CENTRAL INDEX KEY: 0001001233 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 680359556 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: 5109706000 MAIL ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC DATE OF NAME CHANGE: 20000208 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-06-25 0 0001001233 SANGAMO THERAPEUTICS, INC SGMO 0001811505 McClung David Mark C/O SANGAMO THERAPEUTICS, INC. 7000 MARINA BLVD BRISBANE CA 94005 0 1 0 0 EVP, Chief Business Officer Common Stock 2021-06-25 4 F 0 11525 12.02 D 129294 D Represents shares underlying the portion of restricted stock unit ("RSU") grant that vested on June 25, 2021 which were surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on June 25, 2021 of $12.02/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"). Includes: (a) 21,805 shares resulting from the June 25, 2021 vesting of the Reporting Person's June 25, 2020 RSU grant and 66,670 shares subject to such RSU grant that will vest in two remaining annual installments on June 25, 2022 and June 25, 2023; (b) 40,000 shares subject to a grant of RSUs to the Reporting Person on February 25, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date. The vesting of all such RSUs is subject to the Reporting Person's continued service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended; and (3) 819 shares acquired by the Reporting Person on May 28, 2021 under the Issuer's 2020 Employee Stock Purchase Plan. /s/ Matthew Colvin, Attorney-in-Fact for D. Mark McClung 2021-06-29